Answers are grounded in this paper and cite their sources.
A critical component in clinical trials for vaccines against pneumococcal disease is the establishment of robust preclinical models and clinical correlates of protection, which, in the case of the causative bacterial agent Streptococcus pneumoniae , include standard sepsis/pneumonia mouse models and opsonophagocytic activity (OPA), respectively. Despite broad usage, these gold-standard measures are ill equipped to evaluate nontraditional antigens that target virulence factors beyond capsular polysaccharides and/or proteins not associated with colonization or routine growth.
No takes yet. Share an insight, caveat, or question.
Hill et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: